The company plans to help match its customers with nearby study sites based on their disease, demographics and DNA.
The partnership comes as 23andMe moves into drug development, mining its database for therapeutic targets and entering research partnerships with drugmakers, universities and other nonprofits.
23andMe’s foray into clinical trial management could be a major appeal for customers, STAT reports. Its kits could help patients find major diseases hidden in their genes and match them with the best experimental drugs.
Under the partnership, 23andMe will hand off its nearly 8 million engaged customers to TrialSpark, which will help enroll patients in clinical trials near their homes.
Read the full report here.
More articles on pharmacy:
World Pharmacist Day promotes use of safe and effective medicines
USP delays release of updated compounding standards
Americans pay up to 67 times more for drugs than other countries
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.